Business Context and Reporting Period
Anixa Biosciences, Inc. (ANIX) is a biotechnology company developing oncology therapies and vaccines. The company operates through three segments: Cancer Vaccines, CAR-T Therapeutics (via subsidiary Certainty Therapeutics), and Other. This Form 10-Q covers the quarterly period ended July 31, 2025.
Key operational milestones include:
- CAR-T Therapeutics: Phase 1 clinical trials for ovarian cancer are ongoing. The fourth dose cohort (30x higher than the first) was treated between June and September 2025 with well-tolerated results. One patient has survived two years post-treatment and received a re-dose in October 2024.
- Cancer Vaccines: Phase 1 trials for a breast cancer vaccine (targeting triple-negative breast cancer) have completed enrollment and treatment. Final data is expected in December 2025, with plans to initiate a Phase 2 neo-adjuvant trial thereafter. An ovarian cancer vaccine is in pre-clinical development supported by the NCI.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 31, 2025 | Nine Months Ended July 31, 2025 | Balance Sheet (July 31, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,280) | $(8,306) | N/A |
| Net Loss Attributable to Common Shareholders | $(2,258) | $(8,232) | N/A |
| Operating Expenses | $2,436 | $8,825 | N/A |
| Research & Development Expenses | $1,055 | $3,929 | N/A |
| General & Administrative Expenses | $1,381 | $4,896 | N/A |
| Interest Income | $156 | $519 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,495 |
| Short-term Investments | N/A | N/A | $14,534 |
| Total Liquidity (Cash + Investments) | N/A | N/A | $16,029 |
| Total Liabilities | N/A | N/A | $2,240 |
| Shares Outstanding | N/A | N/A | 32,822,109 |
Note: All financial figures are in thousands, except per share data and share counts.
Material Changes vs. Prior Period
Three Months Ended July 31, 2025 vs. 2024:
- Net Loss: Decreased by $1,035,000 (31%) to $2,280,000, driven by lower operating expenses.
- R&D Expenses: Decreased by $870,000 (45%) to $1,055,000. Reductions were due to lower outside R&D costs for breast cancer vaccines ($631,000) and CAR-T therapeutics ($170,000), and reduced stock-based compensation.
- G&A Expenses: Decreased by $286,000 (17%) to $1,381,000, primarily due to lower director stock-based compensation and investor relations expenses.
- Interest Income: Decreased by $121,000 to $156,000 due to lower investment balances and interest rates.
Nine Months Ended July 31, 2025 vs. 2024:
- Net Loss: Decreased by $1,479,000 (15%) to $8,306,000.
- R&D Expenses: Decreased by $991,000 (20%) to $3,929,000. Savings came from reduced outside R&D for vaccines and CAR-T, offset slightly by increased costs for a new vaccine discovery program.
- G&A Expenses: Decreased by $852,000 (15%) to $4,896,000, driven by lower investor relations and stock-based compensation costs.
- Liquidity: Total cash and short-term investments decreased by approximately $3,895,000 from $19,924,000 (Oct 31, 2024) to $16,029,000 (July 31, 2025).
Guidance, Outlook, and Risks
Outlook and Liquidity:
- Management believes existing cash, cash equivalents, and short-term investments ($16.0 million) are sufficient to fund operations for at least the next 12 months.
- The company raised approximately $1.9 million net of expenses during the nine months ended July 31, 2025, via an at-the-market (ATM) equity offering.
- Under the current ATM program, the company may sell up to approximately $95 million of common stock.
- Revenue is not expected from current vaccine or therapy programs in the near term; profitability is anticipated through future licensing to pharmaceutical partners.
Risks and Contingencies:
- Clinical Trial Risks: Success depends on positive results from human clinical trials, which may take several years. There is no guarantee of regulatory approval or commercial success.
- Capital Requirements: The company has a history of net losses and an accumulated deficit of $248.9 million. Continued funding is required to advance clinical programs.
- Legal Proceedings: No material pending litigation other than patent enforcement activities.
- Commitments: Future payments under R&D agreements may total approximately $1.8 million over up to three years. License commitments for the next 12 months are approximately $150,000.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $16.0 million liquidity position against the projected burn rate for the upcoming Phase 2 breast cancer vaccine trial and ongoing CAR-T studies.
- ATM Offering Capacity: Confirm the remaining capacity under the $95 million ATM program and the pricing environment for future equity raises.
- Clinical Data Release: Monitor the anticipated release of final Phase 1 breast cancer vaccine data in December 2025 and the subsequent FDA consultation for Phase 2 initiation.
- Stock-Based Compensation: Review the impact of non-cash stock-based compensation ($2.9 million for the nine months) on the company's cash burn and future dilution.
- Noncontrolling Interest: Note the 4.1% equity stake held by The Wistar Institute in the Certainty Therapeutics subsidiary and its impact on net loss attribution.